Alzheimer's disease

News

FDA sets August date for subcutaneous Leqembi decision

FDA has started its review of an autoinjector version of Eisai and Biogen's Alzheimer's drug Leqembi that could allow patients to be dosed at home.

News

Lilly's Alzheimer's drug Kisunla is cleared in China

Eli Lilly has another approval for its anti-amyloid therapy for Alzheimer's disease, Kisunla, in China – the world's second-largest drugs market.

News

GSK builds neuro, cancer pipeline with trio of deals

GSK has added to its R&D pipeline via partnerships with Muna Therapeutics, Rgenta Therapeutics, and Duality Biologics.

News

End looms for Cassava's simufilam in Alzheimer's disease

Cassava Sciences' troubled development of Alzheimer's disease candidate simufilam looks like it may have finally reached the end

News

Eisai dials back forecasts for Alzheimer's drug Leqembi

Eisai has retreated from the optimistic view of sales growth for Alzheimer's disease drug Leqembi it held earlier this year as uptake remains sluggish.

R&D

Cassava’s Alzheimer’s drug nears P3 readout, but SEC scandal...

Cassava is advancing simufilam through a pivotal phase 3 trial, despite lingering controversy from a SEC investigation.

FDA sets August date for subcutaneous Leqembi decision

Lilly's Alzheimer's drug Kisunla is cleared in China

GSK builds neuro, cancer pipeline with trio of deals

End looms for Cassava's simufilam in Alzheimer's disease

Eisai dials back forecasts for Alzheimer's drug Leqembi

Cassava’s Alzheimer’s drug nears P3 readout, but SEC scandal...

NHS staff 'feel unprepared for digital transformation'

How to meet your physicians where they are online

Alzheimer's disease

Editor's Picks